Jci_page_head_homepage_01 Jci_page_head_homepage_02
Jan-Luuk Hillebrands, Flip A. Klatter, Bart M.H. van den Hurk, Eliane R. Popa, Paul Nieuwenhuis, Jan Rozing
Published in Volume 107, Issue 11
J Clin Invest. 2001; 107(11):1411–1422 doi:10.1172/JCI10233
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2

Neointimal ECs in aortic allografts are of recipient origin. Immunohistochemical staining using MHC class I haplotype-specific mAb’s was performed to determine the origin (donor vs. recipient) of neointimal ECs after allogeneic aorta transplantation. PVG allografts transplanted in AO recipients showed severe TA. (a) MHC class I expression on ECs (OX18-positive). Note the absence of VSM cells in the media (m). Donor endothelium had disappeared (OX27-negative) (b) and had been replaced by recipient-derived ECs (U9F4-positive) (c). Lew allografts transplanted into BN recipient rats also showed severe TA. (d) MHC class I expression on ECs (OX18-positive). (e) Donor endothelium had been replaced by recipient-derived ECs (OX27-positive). After CsA treatment, no neointima formation was observed 1 month after transplantation. (f) ECs covering the internal elastic lamina expressed MHC class I antigens (OX18-positive). However, ECs were OX27 (recipient class I)–negative (g), indicating that after CsA treatment EC replacement does not occur. Arrowheads indicate positively stained ECs. Original magnification: ×400.